DBV Technologies S.A.
Nasdaq: DBVTBiological Products, (No Diagnostic Substances) · Entity-resolved by Clous
CIK0001613780
TickerDBVT
ExchangeNasdaq
SIC2836
StateI0
FY end12-31
Key financials
RevenueFY2025-12-31
$5.64M
+35.8% YoY
Net IncomeFY2025-12-31
-$146.95M
-29.0% YoY
Total AssetsFY2025-12-31
$233.72M
+256.0% YoY
EquityFY2025-12-31
$168.77M
+516.2% YoY
Shares OutstandingFY2025-12-31
296.04M
—
Operating Cash FlowFY2025-12-31
-$121.18M
-16.0% YoY
Market
Market
DBVTClose price
$15.53
Market cap
$4.6B
delayed EOD · as of 2026-06-18
Short interest & fails
Cost to borrow9.85%20K shares availablehard to borrow
Short-sale volume
FINRA Reg SHO · daily13.9%
short of total volume · 2026-06-18
2026-06-1813.9%
2026-06-1746.8%
2026-06-1658.0%
2026-06-1549.5%
2026-06-121.6%
Fails-to-deliver
SEC CNS fails · semi-monthly896
shares failed · 2026-05-29
2026-05-29896 sh$18.99
2026-05-191.85K sh$18.75
2026-05-186.66K sh$19.65
2026-05-1410.22K sh$19.60
2026-05-08261 sh$19.99
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | $4.84M | $15.73M | $4.15M | $5.64M | +35.8% | 100% |
| Net Income | -$96.27M | -$72.73M | -$113.92M | -$146.95M | -29.0% | -2607% |
| Total Assets | $246.52M | $182.99M | $65.66M | $233.72M | +256.0% | 4147% |
| Equity | $194.45M | $140.19M | $27.39M | $168.77M | +516.2% | 2994% |
| Operating Cash Flow | -$55.67M | -$79.65M | -$104.47M | -$121.18M | -16.0% | -2150% |
| Shares Outstanding | — | — | — | 296.04M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001613780